UCB: psoriasis drug superior to Abbvie treatment in study
(CercleFinance.com) - Belgian biopharmaceutical company UCB said that its investigational drug bimekizumab was found to be more effective than a rival medicine from Abbvie in reducing the symptoms in adults with moderate-to-severe plaque psoriasis in a late-stage study.
The phase III trial met its co-primary endpoints at week 16, demonstrating superiority of bimekizumab versus Humira in achieving at least a 90% improvement in the psoriasis area and severity index (PASI 90) and investigator global assessment (IGA) response of clear or almost clear.
This is the third phase III bimekizumab psoriasis study to report positive results since October, UCB said. The group said it plans to submit applications to regulatory authorities for the approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020.
Copyright (c) 2019 CercleFinance.com. All rights reserved.